Biotech | October 11, 2021
Astra’s antibody injection trial indicates it can prevent and treat Covid-19
AZD7442 reduced risk of developing severe Covid-19 or death in Tackle Phase III outpatient treatment trial
AZD7442 reduced risk of developing severe Covid-19 or death in Tackle Phase III outpatient treatment trial
The company has enabled a transformation across three core areas with an investment target of US $ 150 million
The company will shift 100 percent of its energy use to renewable sources for both power and heat by 2025 in order to achieve carbon neutrality
The rolling submission to the U.S. FDA will begin in the fourth quarter of this year
Quantitative restrictions in place to meet domestic needs to cater to the vaccination programme
The first study to investigate the safety and immunogenicity of both vaccines when co-administered compared to each vaccine administered separately in adults aged 65 years and older
This opens up a huge market for the company’s Magnezis implants in India
The company has already received the emergency use authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D to be administered in three doses on August 20
Bharat Biotech has been submitting data to the WHO on a rolling basis and submitted additional information at WHO’s request on September 27th 2021
The rates for over 400 procedures were revised
Subscribe To Our Newsletter & Stay Updated
